Categories: News

NeuroStar Advanced Therapy for Mental Health Recognized as Top Neuromodulation Solution Provider in 2021

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Technology is awarded for its advances in mental health

MALVERN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, is named Top Neuromodulation Solution Provider in 2021 by MedTech Outlook magazine. NeuroStar is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder. With over 4.3 million treatments delivered and countless lives transformed, a recent publication shows that NeuroStar achieved a high response rate of 83% and remission rate of 62% (Sackeim, et al).

“We are grateful to be recognized as a leader in the neuromodulation space,” said Keith J. Sullivan, President and CEO of Neuronetics. “Our goal is to offer a non-drug treatment to the millions of patients suffering from major depressive disorder – giving them a potential solution for a condition that can be challenging to manage. We are devoted to advancing our technology and spreading awareness to help change people’s lives.”

Along with the recognition is an article on MedicalTechOutlook.com, featuring NeuroStar’s technology, an overview of the programs and resources the company provides to physician practices and the vision for the company over the next five years.

To access the full list of the Top 10 Neuromodulation Solution Companies of 2021, visit MedTech Outlook here. For more information on NeuroStar, please visit neurostar.com

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from psychiatric disorders. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics’ NeuroStar® Advanced Therapy system is today’s leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over four million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit NeuroStar.com.

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

1 day ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

1 day ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

1 day ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

1 day ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

1 day ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

1 day ago